Exact Sciences Corp. EXAS on Thursday reported a second-quarter 2025 EPS loss of 1 cent, up from a 9-cent loss a year ago, beating the analyst consensus loss estimate of 19 cents.Revenues increased to $811.085 million, beating the consensus of$774.34 million.Sales jumped 16% on a reported and core revenue basis, including Screening revenue of $628 million and Precision Oncology revenue of$183 million.Also Read: Could Personalized Medicine Be Your Portfolio’s Next Big Winner? Find OutGross margin was 69%, ...